Chemotherapy-Induced-Anemia-Pipeline-Review-H2-2017

Chemotherapy-Induced-Anemia-Pipeline-Review-H2-2017


  • Products Id :- GMDHC9670IDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chemotherapy Induced Anemia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia-Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 2 and 4 respectively.

Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology).

The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Anemia-Overview

Chemotherapy Induced Anemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chemotherapy Induced Anemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Anemia-Companies Involved in Therapeutics Development

3SBio Inc

Chong Kun Dang Pharmaceutical Corp

Galenica Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

SBI Pharmaceuticals Co Ltd

Therapure Biopharma Inc

Tolero Pharmaceuticals Inc

Chemotherapy Induced Anemia-Drug Profiles

(aminolevulinic acid hydrochloride + sodium ferrous citrate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin zeta biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegylated erythropoietin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHEP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBI-304H-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0184-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Anemia-Dormant Projects

Chemotherapy Induced Anemia-Discontinued Products

Chemotherapy Induced Anemia-Product Development Milestones

Featured News & Press Releases

Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H

Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia

Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health

Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology

Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine

Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting

Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting

Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology

Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended

Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar

Jan 07, 2008: Sandoz and Gambro form strategic alliance

Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Chemotherapy Induced Anemia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Chemotherapy Induced Anemia, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chemotherapy Induced Anemia-Pipeline by 3SBio Inc, H2 2017

Chemotherapy Induced Anemia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Chemotherapy Induced Anemia-Pipeline by Galenica Ltd, H2 2017

Chemotherapy Induced Anemia-Pipeline by Novartis AG, H2 2017

Chemotherapy Induced Anemia-Pipeline by Panacea Biotec Ltd, H2 2017

Chemotherapy Induced Anemia-Pipeline by Pfizer Inc, H2 2017

Chemotherapy Induced Anemia-Pipeline by PharmaEssentia Corp, H2 2017

Chemotherapy Induced Anemia-Pipeline by PhytoHealth Corp, H2 2017

Chemotherapy Induced Anemia-Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017

Chemotherapy Induced Anemia-Pipeline by Therapure Biopharma Inc, H2 2017

Chemotherapy Induced Anemia-Pipeline by Tolero Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Anemia-Dormant Projects, H2 2017

Chemotherapy Induced Anemia-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3SBio Inc

Chong Kun Dang Pharmaceutical Corp

Galenica Ltd

Novartis AG

Panacea Biotec Ltd

Pfizer Inc

PharmaEssentia Corp

PhytoHealth Corp

SBI Pharmaceuticals Co Ltd

Therapure Biopharma Inc

Tolero Pharmaceuticals Inc

Chemotherapy Induced Anemia Therapeutic Products under Development, Key Players in Chemotherapy Induced Anemia Therapeutics, Chemotherapy Induced Anemia Pipeline Overview, Chemotherapy Induced Anemia Pipeline, Chemotherapy Induced Anemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 142520
Site License
USD 4000 INR 285040
Corporate User License
USD 6000 INR 427560

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com